Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
NDSN
Nordson Corporation
Atrion's medical components and medical device technologies place Nordson in the medical devices & biometrics space.
|
$15.74B |
$282.00
+1.92%
|
|
ASND
Ascendis Pharma A/S
Ascendis Pharma focuses on rare-disease endocrinology therapies (YORVIPATH, SKYTROFA, TransCon CNP) within biotech, fitting the Biotech - Rare Diseases category.
|
$14.94B |
$244.53
+0.65%
|
|
BBIO
BridgeBio Pharma, Inc.
BBP-812 is an AAV9 gene therapy candidate for Canavan disease, a gene therapy product.
|
$14.79B |
$76.69
-1.06%
|
|
MEDP
Medpace Holdings, Inc.
Medpace's core business is a specialized full-service CRO delivering Phase I–IV clinical development services.
|
$14.66B |
$520.52
+0.94%
|
|
PODD
Insulet Corporation
Insulet's core business is medical devices and equipment, anchored by the Omnipod insulin pump platform.
|
$14.33B |
$203.62
+1.07%
|
|
RGC
Regencell Bioscience Holdings Limited
Regencell Bioscience focuses on neuropsychiatric drug development for ADHD/ASD, aligning with Neuropsychiatric Drug Development.
|
$14.18B |
$28.77
-5.89%
|
|
COO
The Cooper Companies, Inc.
CooperVision and CooperSurgical primarily manufacture ophthalmology devices and related vision-care products, fitting Ophthalmology Devices.
|
$13.73B |
$70.06
+0.97%
|
|
ALGN
Align Technology, Inc.
Align's Invisalign system, iTero scanners, and direct 3D-printed dental devices are core dental equipment products.
|
$13.64B |
$190.03
+2.71%
|
|
FMS
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care manufactures and provides Blood Purification Devices used in dialysis, including the 5008X CAREsystem.
|
$13.57B |
$23.42
+2.85%
|
|
UNM
Unum Group
Health Insurance products are part of Unum's workplace benefits and risk protections in the employee benefits mix.
|
$13.32B |
$79.63
+0.82%
|
|
NBIX
Neurocrine Biosciences, Inc.
Neurocrine's core focus is neuroscience with programs in neuropsychiatric disorders (MDD, schizophrenia, TD) and related CNS conditions.
|
$13.29B |
$133.24
+3.76%
|
|
PEN
Penumbra, Inc.
Penumbra's core offerings include vascular intervention devices used for thrombectomy and catheter-based clot removal.
|
$13.01B |
$332.21
+0.22%
|
|
GMED
Globus Medical, Inc.
Orthopedic devices and implants (spinal, ALIF spacers, knee systems) sold for reconstruction.
|
$12.75B |
$95.27
+2.71%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a bispecific antibody, a core oncology modality represented by Bispecific Antibodies.
|
$12.36B |
$203.41
+2.82%
|
|
IONS
Ionis Pharmaceuticals, Inc.
Ionis's core platform is RNA-targeted antisense oligonucleotides, directly aligning with the Oligonucleotide Therapeutics category.
|
$12.26B |
$75.72
+0.61%
|
|
SOLV
Solventum Corporation
V.A.C. Peel and Place dressing is a wound care device, a core MedSurg product.
|
$12.22B |
$70.51
+2.37%
|
|
GL
Globe Life Inc.
Supplemental health/health insurance products marketed by Globe Life.
|
$12.09B |
$151.86
+1.46%
|
|
MDGL
Madrigal Pharmaceuticals, Inc.
Rezdiffra is an oral, small-molecule therapeutic (THR-β agonist) approved for MASH, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$12.08B |
$531.77
+1.34%
|
|
DOC
Healthpeak Properties, Inc.
The CCRCs and healthcare facilities component places Healthpeak in Healthcare Services & Facilities.
|
$12.07B |
$17.36
+1.61%
|
|
EXEL
Exelixis, Inc.
Exelixis is a biotech company focused on oncology therapies, including cabozantinib (CABOMETYX) and pipeline assets.
|
$12.04B |
$44.90
+1.16%
|
|
ELAN
Elanco Animal Health Incorporated
Vaccines are a major product category and a focus of Elanco's innovation pipeline.
|
$11.77B |
$23.69
+2.42%
|
|
ENSG
The Ensign Group, Inc.
ENSG's core business is providing post-acute healthcare services and facilities management (skilled nursing, rehabilitative services, senior living) across facilities.
|
$11.59B |
$200.18
+1.24%
|
|
UHS
Universal Health Services, Inc.
UHS directly provides hospital inpatient and related acute care services.
|
$11.40B |
$182.39
+2.05%
|
|
GH
Guardant Health, Inc.
Core product category: Guardant Health's liquid biopsy tests (Guardant360 Liquid/Tissue) are the primary offerings.
|
$11.39B |
$90.31
+5.38%
|
|
RDY
Dr. Reddy's Laboratories Limited
Core business focused on manufacturing and selling generic drugs.
|
$11.10B |
$13.29
+1.80%
|
|
EHC
Encompass Health Corporation
Encompass Health operates inpatient rehabilitation hospital services, aligning with the Hospital Services investable theme.
|
$10.70B |
$106.38
+0.84%
|
|
RVTY
Revvity, Inc.
Revvity's Diagnostics segment includes diagnostic equipment and instruments.
|
$10.65B |
$93.97
+5.04%
|
|
BMRN
BioMarin Pharmaceutical Inc.
BioMarin's core commercial therapies (VOXZOGO for skeletal disorders and enzyme replacement therapies like PALYNZIQ, VIMIZIM, NAGLAZYME) are all in the rare diseases space, fitting the Biotech - Rare Diseases investable theme.
|
$10.50B |
$54.65
+1.01%
|
|
OKLO
Oklo Inc.
Atomic Alchemy's production of high-value radioisotopes for medical, industrial, defense, and AI applications aligns with radiopharmaceuticals.
|
$10.44B |
$66.78
+4.00%
|
|
WBA
Walgreens Boots Alliance, Inc.
Home Health & Hospice – Through CareCentrix and related services, Walgreens provides home health coordination and related care services.
|
$10.36B |
$11.98
|
|
DVA
DaVita Inc.
DaVita operates clinical laboratory testing facilities and diagnostic services as part of its dialysis and kidney care offerings.
|
$10.35B |
$147.88
-0.17%
|
|
TEM
Tempus AI, Inc.
Clinical Lab Chains – Tempus operates clinical laboratories delivering sequencing-based diagnostics, expanded by the Ambry Genetics acquisition.
|
$9.94B |
$55.87
+2.66%
|
Showing page 5 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
